<DOC>
	<DOCNO>NCT00738985</DOCNO>
	<brief_summary>To measure percentage patient achieve treatment lipid goal treat ezetimibe/simvastatin 10/20 without MK0524A ( 1-2 g/day ) .</brief_summary>
	<brief_title>Efficacy Ezetimibe/Simvastatin 10/20 mg MK0524A ( 1-2 g/Day ) Mixed Hyperlipidemia Two More Risk Factors</brief_title>
	<detailed_description>Patients receive placebo 4 week , Vytorin 10/20 mg 6 week , efficacy treatment achieve , continue Vytorin 10/20 mg + placebo 12 week , achieve , receive Vytorin 10/20 mg + MK0524A 1 gr 6 week , efficacy achieve continue Vytorin 10/20 mg + MK0524A 1 gr + placebo ; achieve , receive Vytorin 10/20 mg + MK0524A 2 gr 6 week .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Patient Without Ischemic Cardiovascular Disease Who During The Treatment With Statin Have LDLC &lt; 130 Mg/Dl Visit 1 Or Within The 6 Month Period Before Visit 1 Exclusion criterion : The use lipid lowering agent Life expectancy low year . Any condition may interfere adherence study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>